Alphatec (NASDAQ:ATEC) Price Target Cut to $15.00 by Analysts at JPMorgan Chase & Co.

Alphatec (NASDAQ:ATEC) had its target price dropped by stock analysts at JPMorgan Chase & Co. from $16.00 to $15.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the medical technology company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 113.07% from the stock’s current price.

ATEC has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a research report on Monday, August 3rd. Needham & Company LLC decreased their price objective on Alphatec from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday. Stifel Nicolaus dropped their price objective on Alphatec from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. BMO Capital Markets downgraded Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price objective on the stock. in a research report on Friday. Finally, Wall Street Zen lowered Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, October 11th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Alphatec Stock Down 38.1%

Shares of ATEC stock traded down $4.33 on Friday, hitting $7.04. The stock had a trading volume of 27,294,109 shares, compared to its average volume of 3,029,589. The business has a 50 day moving average price of $10.18 and a 200 day moving average price of $10.67. The company has a market cap of $1.09 billion, a PE ratio of -9.92 and a beta of 0.78. Alphatec has a one year low of $6.81 and a one year high of $23.29.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The business had revenue of $221.17 million for the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%. The firm’s revenue was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 earnings per share. Equities research analysts expect that Alphatec will post -0.45 EPS for the current year.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles acquired 115,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the acquisition, the chief executive officer owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the sale, the general counsel owned 630,398 shares of the company’s stock, valued at approximately $6,083,340.70. This represents a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATEC. State of Wyoming raised its stake in Alphatec by 87.7% in the third quarter. State of Wyoming now owns 30,666 shares of the medical technology company’s stock valued at $316,000 after buying an additional 14,328 shares during the last quarter. Sterling Capital Management LLC boosted its position in Alphatec by 841.5% in the 3rd quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock worth $42,000 after purchasing an additional 3,669 shares in the last quarter. Kopp Family Office LLC increased its holdings in Alphatec by 0.4% in the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock valued at $3,408,000 after buying an additional 1,303 shares in the last quarter. AA Financial Advisors LLC raised its holdings in Alphatec by 140.5% in the 3rd quarter. AA Financial Advisors LLC now owns 48,094 shares of the medical technology company’s stock worth $496,000 after purchasing an additional 28,094 shares during the period. Finally, Congress Asset Management Co. raised its position in Alphatec by 20.7% during the third quarter. Congress Asset Management Co. now owns 532,069 shares of the medical technology company’s stock worth $5,491,000 after acquiring an additional 91,431 shares during the period. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.